Comparative Effect of Insulin Sensitizers and Statin on Metabolic Profile and Ultrasonographical Score in Non Alcoholic Fatty Liver Disease

Rana, Himanshu; Yadav, Suraj Singh; Reddy, Himanshu; Singhal, Shubham; Singh, Dinesh Kumar; Usman, Kauser

doi:10.7860/jcdr/2016/19887.8336

Cited by 17 publications

(25 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Insulin-sensitizing drugs, such as metformin, may correct some of these metabolic disorders [70]. Additionally, the cardiovascular protective effect of metformin in patients with diabetes cannot be attributed only to reduced blood glucose but may also be correlated with the protective role of metformin in lipid metabolism and vascular endothelial function [11, 71]. Studies also suggest that the use of metformin by obese patients with or without diabetes can significantly reduce systemic and visceral fat [72, 73].…”

Section: Discussionmentioning

confidence: 99%

“…According to the double-hit theory, the first hit of NAFLD is the accumulation of abnormal triglycerides in hepatocytes, which results in the second hit in which inflammatory mediators further lead to liver injury, inflammation, and fibrosis [8, 9]. Metformin is a hypoglycaemic drug that has been clinically applied for half a century and not only improves insulin resistance and hyperinsulinaemia but can also directly influence insulin target cells, particularly by increasing insulin sensitivity via post-receptor mechanisms [10, 11]. Thus, metformin is recommended and effective for the treatment of NAFLD [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Metformin-Induced Changes of the Coding Transcriptome and Non-Coding RNAs in the Livers of Non-Alcoholic Fatty Liver Disease Mice

Guo

Zhou

Cheng

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Recent studies have suggested that changes in non-coding mRNA play a key role in the progression of non-alcoholic fatty liver disease (NAFLD). Metformin is now recommended and effective for the treatment of NAFLD. We hope the current analyses of the non-coding mRNA transcriptome will provide a better presentation of the potential roles of mRNAs and long non-coding RNAs (lncRNAs) that underlie NAFLD and metformin intervention. Methods: The present study mainly analysed changes in the coding transcriptome and non-coding RNAs after the application of a five-week metformin intervention. Liver samples from three groups of mice were harvested for transcriptome profiling, which covered mRNA, lncRNA, microRNA (miRNA) and circular RNA (circRNA), using a microarray technique. Results: A systematic alleviation of high-fat diet (HFD)-induced transcriptome alterations by metformin was observed. The metformin treatment largely reversed the correlations with diabetes-related pathways. Our analysis also suggested interaction networks between differentially expressed lncRNAs and known hepatic disease genes and interactions between circRNA and their disease-related miRNA partners. Eight HFD-responsive lncRNAs and three metformin-responsive lncRNAs were noted due to their widespread associations with disease genes. Moreover, seven miRNAs that interacted with multiple differentially expressed circRNAs were highlighted because they were likely to be associated with metabolic or liver diseases. Conclusions: The present study identified novel changes in the coding transcriptome and non-coding RNAs in the livers of NAFLD mice after metformin treatment that might shed light on the underlying mechanism by which metformin impedes the progression of NAFLD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Metformin-Induced Changes of the Coding Transcriptome and Non-Coding RNAs in the Livers of Non-Alcoholic Fatty Liver Disease Mice

Guo

Zhou

Cheng

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Moreover, NASH is linked to inflammation in peripheral adipose tissues that involves mainly macrophages and humoral factors, such as adipokines and cytokines [4,5]. Therefore, the treatment strategies for NAFLD aim to improve insulin sensitivity, modify underlying metabolic risk factors or to protect the liver from further insult by reducing oxidative stress and inflammatory markers [6]. So far, there is no established pharmacological treatment for NAFLD.…”

Section: Introductionmentioning

confidence: 99%

“…So far, there is no established pharmacological treatment for NAFLD. The most efficient treatment is lifestyle modification by diet, exercise and weight loss as the mainstay of therapy [1,6], but (adjunctive) pharmacological strategies are urgently needed. Multiple pharmacological interventions have been attempted with variable success.…”

Section: Introductionmentioning

confidence: 99%

“…Multiple pharmacological interventions have been attempted with variable success. These include pentoxifylline, orlistat, Vitamin E, ursodeoxycholic acid, omega -3 fatty acids, and insulin sensitizers and lipid-lowering agents [6]. However, the American Association for the Study of Liver Diseases (AASLD) recommends the use of Vitamin E administered at daily doses of 800 IU/day in non-diabetic adults with biopsy-proven NASH and is considered as a first line pharmacotherapy for this patient population [7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An Open-label Randomized Clinical Study to Compare the Effects of a Nutritional Supplement versus Vitamin E on Fibroscan Score in Nonalcoholic Steatohepatitis (NASH) Patients

Ashraf¹,

Alam²,

Sarkar³

et al. 2018

ujph

View full text Add to dashboard Cite

Background: Despite the benefit of lifestyle changes, there is no standard treatment for Fibrotic NASH. However the concept of reversibility of liver fibrosis and cirrhosis with various natural biologically active compounds and antioxidant micro-nutrients is not new. Aim: The aim of this study was to compare effectiveness of Viusid ® (a nutritional supplement) and Vitamin E in reducing steatosis and liver fibrosis score in patients with fibrotic NASH. Methods: 52 patients diagnosed with nondiabetic and noncirrhotic NASH on liver fibroscan were divided into 2 groups randomly and given Viusid ® 3 sachets daily to 25 patients or Vitamin E 800 IU daily to 27 patients along with a hypocaloric diet and exercise for 3 months. Results: After 3 months treatment with Viusid ® , as compared with Vitamin E, was associated with a significant reduction of both mean steatosis score (CAP value reduces from 286±16.3 to 208±18.5 dB/m in Viusid ® group vs. from 278±14.4 to 253±12.1 dB/m in Vitamin E group; p<0.00001) and fibrosis score (E value reduces from 6.8±0.5 to 5.1±0.7 kPa in Viusid ® group vs. from 6.9±0.5 to 6.5±0.4 kPa in Vitamin E group; p<0.00001).

show abstract

Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie

Apostolopoulou

Roden

2022

Nicht-Alkoholische Fettlebererkrankung

View full text Add to dashboard Cite

Comparative Effect of Insulin Sensitizers and Statin on Metabolic Profile and Ultrasonographical Score in Non Alcoholic Fatty Liver Disease

Cited by 17 publications

References 23 publications

Metformin-Induced Changes of the Coding Transcriptome and Non-Coding RNAs in the Livers of Non-Alcoholic Fatty Liver Disease Mice

Metformin-Induced Changes of the Coding Transcriptome and Non-Coding RNAs in the Livers of Non-Alcoholic Fatty Liver Disease Mice

An Open-label Randomized Clinical Study to Compare the Effects of a Nutritional Supplement versus Vitamin E on Fibroscan Score in Nonalcoholic Steatohepatitis (NASH) Patients

Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie

Contact Info

Product

Resources

About